Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen lowered shares of Spero Therapeutics (NASDAQ:SPRO) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Other research analysts have also issued reports about the company. HC Wainwright upped their target price on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Cantor Fitzgerald started coverage on Spero Therapeutics in a report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price target for the company. Zacks Research upgraded Spero Therapeutics to a “hold” rating in a report on Monday, September 14th. Compass Point raised Spero Therapeutics to a “neutral” rating in a research note on Monday, September 14th. Finally, Weiss Ratings raised shares of Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $6.00.

Spero Therapeutics Stock Down 0.0%

Shares of Spero Therapeutics stock traded down $0.00 on Friday, hitting $1.00. 357,486 shares of the company traded hands, compared to its average volume of 336,103. Spero Therapeutics has a 12-month low of $0.95 and a 12-month high of $3.08. The company has a market cap of $58.23 million, a PE ratio of -1.92 and a beta of 1.59. The company has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.91.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.29). Spero Therapeutics had a return on equity of 10.54% and a net margin of 24.90%. Equities research analysts anticipate that Spero Therapeutics will post -0.97 EPS for the current year.

Insider Activity

In other news, insider Esther Rajavelu sold 40,851 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $1.04, for a total value of $42,485.04. Following the sale, the insider owned 946,000 shares in the company, valued at approximately $983,840. This trade represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.90% of the company’s stock.

Institutional Trading of Spero Therapeutics

Hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new stake in Spero Therapeutics during the third quarter worth $236,000. Empowered Funds LLC bought a new stake in Spero Therapeutics in the 3rd quarter valued at $77,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $36,000. BlackRock Inc. acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $1,314,000. Finally, Alphabet Inc. acquired a new position in Spero Therapeutics in the second quarter worth about $1,967,000. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited. The company’s pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections.